Clinical Trials Using Ixazomib Citrate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Ixazomib Citrate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 25
  • Pomalidomide and Dexamethasone with or without Ixazomib in Treating Patients with Relapsed Multiple Myeloma

    This randomized phase I / II trial studies the side effects and best dose of pomalidomide and ixazomib when given together with dexamethasone and to see how well pomalidomide and dexamethasone with or without ixazomib work in treating patients with multiple myeloma that has come back (relapsed). Biological therapies, such as pomalidomide and dexamethasone, may stimulate the immune system in different ways and stop cancer cells from growing. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether pomalidomide and dexamethasone are more effective with or without ixazomib in treating multiple myeloma.
    Location: 311 locations

  • Myeloma-Developing Regimens Using Genomics (MyDRUG)

    The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 30% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a greater than 30% mutation to the genes listed can be enrolled to a non-actionable treatment arm. The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002 study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies. (NCT02884102).
    Location: 11 locations

  • Ixazomib and Pevonedistat in Treating Patients with Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

    This IB trial studies side effects and best dose of pevonedistat when given together with ixazomib in treating patients with multiple myeloma that has come or does not respond to treatment. Pevonedistat and ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 8 locations

  • A Study of Ixazomib and Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma

    Patients with mantle cell lymphoma (MCL) that has relapsed (come back) or refractory (progressed on treatment) will receive ixazomib and ibrutinib. Ibrutinib has been approved by the Food and Drug Administration (FDA) as treatment for patients with mantle cell lymphoma who have received at least one prior therapy. Ixazomib is in a class of medications called proteasome inhibitors. Cancer cells depend on proteasome to provide this protein metabolism (turnover) function to regulate their growth and survival. Ixazomib disrupts a cancer cells' ability to survive by blocking the proteasome and disrupting protein metabolism. This may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory MCL and to examine the side effects associated with ixazomib in combination with ibrutinib.
    Location: 9 locations

  • Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

    Single arm phase I / II study of ixazomib and romidepsin in relapsed / refractory PTCL. Each cycle is 28 days. Patients will continue to receive therapy until progressive disease, unacceptable toxicity, or if any other withdrawal criteria are met. The phase I study includes three dose levels. The phase II study will include treatment with ixazomib and romidepsin at the MTD established in the Phase I study.
    Location: 5 locations

  • Ixazomib, Pomalidomide, and Dexamethasone for the Treatment of Recurrent or Refractory Multiple Myeloma

    This phase I / II trial studies the side effects and best dose of the combination of ixazomib, pomalidomide and dexamethasone for treating patients with multiple myeloma that has come back (recurrent) or does not respond to treatment (refractory). Ixazomib may stop the growth of tumor cells by blocking or slowing down a part of cells called proteasomes, therefore preventing proteasomes from doing their job, which is digestion of proteins. The buildup of excess proteins may cause cell death. Dexamethasone may stop white blood cells from traveling to areas myeloma cells are causing damage, and when combined with drugs used to treat myeloma, it sometimes makes those drugs work better. Giving ixazomib, pomalidomide, and dexamethasone may work better in treating patients with multiple myeloma compared to chemotherapy alone.
    Location: 4 locations

  • NFKB2 Rearrangement in Guiding Treatment with Ixazomib Citrate and Dexamethasone or Ixazomib Citrate, Dexamethasone and Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

    This randomized phase II trial studies how well ixazomib citrate and dexamethasone or ixazomib citrate, dexamethasone, and lenalidomide work based on the expression of a gene called nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (NFKB2) in treating patients with multiple myeloma that has returned after a period of improvement or does not respond to treatment. Ixazomib citrate may stop the growth of cancer cells by blocking enzymes called proteasomes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lenalidomide may stimulate the immune system against cancer cells and may also prevent the growth of new blood vessels that tumors need to grow. It is not yet known whether ixazomib citrate and dexamethasone, or ixazomib citrate, dexamethasone, and lenalidomide are more effective in treating multiple myeloma.
    Location: 4 locations

  • Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

    This phase II trial studies the side effects of nivolumab, ixazomib, cyclophosphamide, and dexamethasone and to see how well they work for the treatment of multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Nivolumab is a type of antibody (a protein that attaches to other cells to fight off infection and disease) that attaches to and inhibits a protein called PD-1. PD-1 normally acts as a type of “off switch” that helps keep the T cells from attacking other cells in the body. Some cancer cells have large amounts of PD-L1 which binds to PD-1 and turns off the immune system. Nivolumab inhibits PD-1 and helps take the “brake” off the immune system, which may allow immune cells to then recognize and destroy cancer cells. Ixazomib is a type of inhibitor that blocks a protein in cells called a proteasome. Proteasomes are responsible for breaking down other proteins in cells when they need to be disposed of. By blocking the proteasome from working, a buildup of proteins will be created in cancer cells, which may lead to cancer cell death. Chemotherapy drugs, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as dexamethasone, lower the body’s immune response and are used with other drugs in the treatment of some types of cancer. Giving nivolumab and ixazomib with cyclophosphamide and dexamethasone may increase the activity of both ixazomib and nivolumab.
    Location: 3 locations

  • Ixazomib Citrate, Cyclophosphamide and Dexamethasone in Treating Newly Diagnosed Participants with Primary Amyloidosis

    This phase I / II trial studies the side effects and best dose of ixazomib citrate when given together with cyclophosphamide and dexamethasone and to see how well it works in treating participants with primary amyloidosis. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ixazomib citrate together with cyclophosphamide and dexamethasone may work better in treating participants with primary amyloidosis.
    Location: 3 locations

  • Ibrutinib and Ixazomib Citrate in Treating Patients with Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

    This phase II trial studies the side effects of ibrutinib citrate when given with ixazomib, and determines how well they work in treating patients with Waldenstrom macroglobulinemia that is newly diagnosed, has come back (recurrent) or does not respond to treatment (refractory). Enzyme inhibitors, such as ibrutinib and ixazomib citrate, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients with Multiple Myeloma Resistant to Chemotherapy

    This phase II trial studies how well abatacept, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that is resistant to chemotherapy. Abatacept may block certain proteins that are present on multiple myeloma cells that have been shown to protect against chemotherapy. Drugs used in chemotherapy, such as ixazomib citrate and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving abatacept, ixazomib citrate, and dexamethasone may work better at treating patients with multiple myeloma resistant to chemotherapy.
    Location: 2 locations

  • Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients with Smoldering Multiple Myeloma

    This phase II trial studies how well ixazomib citrate, lenalidomide, and dexamethasone work in treating patients with smoldering multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as dexamethasone, lower the body’s immune response and are used with other drugs in the treatment of some types of cancer. Giving ixazomib citrate, lenalidomide, and dexamethasone may work better in treating patients with smoldering multiple myeloma.
    Location: 2 locations

  • Ixazomib Citrate and Rituximab after Stem Cell Transplant in Treating Patients with Mantel Cell Lymphoma in Remission

    This phase I / II trial studies the side effects and best dose of ixazomib citrate when given together with rituximab and to see how well they work after stem cell transplant in treating patients with mantle cell lymphoma that are no longer showing signs or symptoms of cancer. Ixazomib citrate may stop the growth of cancer cell by blocking enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving ixazomib citrate together with rituximab after transplant may help prevent the cancer from coming back.
    Location: 2 locations

  • Ixazomib Citrate in Treating Patients with Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

    This randomized phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement but is not resistant to bortezomib. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Mivavotinib and Ixazomib for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

    This phase I / II trial studies the side effects and best dose of ixazomib and to see how well it works with mivavotinib in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory). Ixazomib belongs to a group of drugs called proteasome inhibitors. Proteasomes act like garbage disposals in the cell by breaking down damaged proteins. Ixazomib blocks proteasome which causes a buildup of protein (“garbage”) within the cancer cell, leading to cell death. Mivavotinib belongs to a group of drugs called kinase inhibitors. Kinase is an enzyme that cells need to perform many tasks such as: talking to other cells, making energy, using energy, dividing, and surviving. Mivavotinib blocks two kinases that are important in blood cells, which may cause the cancer cells to die. Giving mivavotinib and ixazomib together may shrink the cancer and may have more benefit than usual treatments for acute myeloid leukemia.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

  • Ixazomib and Rituximab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma

    This phase II trial studies how well ixazomib and rituximab work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond (refractory) to BTK inhibitor treatment. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with rituximab may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving ixazomib and rituximab may work better in treating patients with mantle cell lymphoma compared to rituximab alone.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients with Locally Advanced or Metastatic Kidney Cancer

    This phase II trial studies how well ixazomib, gemcitabine, and doxorubicin work in treating patients with kidney cancer that has spread to other places in the body (locally advanced or metastatic). Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ixazomib, gemcitabine, and doxorubicin may work better in treating patients with kidney cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

    This phase II trial studies how well pembrolizumab works when given together with ixazomib citrate and dexamethasone in treating patients with multiple myeloma that has come back. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ixazomib citrate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab together with ixazomib citrate and dexamethasone may work better in treating patients with multiple myeloma.
    Location: Mayo Clinic in Rochester, Rochester, Minnesota

  • An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6)

    The purpose of this study is to determine the progression-free survival (PFS) at 2 years for MM participants previously receiving a bortezomib-based induction regimen to IRD.
    Location: 2 locations

  • Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients with POEMS Syndrome

    This pilot phase II trial studies how well ixazomib citrate, lenalidomide, and dexamethasone work in treating patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ixazomib citrate, lenalidomide, and dexamethasone may work better in treating patients with POEMS syndrome.
    Location: Mayo Clinic in Rochester, Rochester, Minnesota

  • Ixazomib Citrate, Daunorubicin Hydrochloride, and Cytarabine in Treating Older Patients with Acute Myeloid Leukemia

    This phase I trial studies the side effects and best dose of ixazomib citrate when given together with daunorubicin hydrochloride and cytarabine in treating older patients with acute myeloid leukemia. Ixazomib citrate blocks enzymes called proteasomes, which may help keep cancer cells from growing. Drugs used in chemotherapy, such as daunorubicin hydrochloride and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ixazomib citrate together with daunorubicin hydrochloride and cytarabine may be a better treatment for acute myeloid leukemia.
    Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts

  • Study of Lenalidomide / Ixazomib / Dexamethasone / Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

    A randomized Phase II clinical trial will be conducted to assess the impact on progression free survival (PFS) with the addition of ixazomib and daratumumab to lenalidomide as a maintenance treatment following induction with lenalidomide, ixazomib, dexamethasone, and daratumumab. Patients will be randomized to either: Arm A: 12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of maintenance therapy. Arm B: 12 cycles of lenalidomide, ixazomib, daratumumab and dexamethasone, followed by lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or a maximum of 2 years maintenance therapy.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

    This phase I / II trial studies the side effects and best dose of venetoclax when given together with ixazomib citrate and dexamethasone and to see how well they work in treating patients with multiple myeloma that has come back. Venetoclax and ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with ixazomib citrate and dexamethasone may work better in treating patients with multiple myeloma.
    Location: 7 locations

  • Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients with Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

    This phase I / II trial studies the side effects and the best dose of cyclophosphamide when given together with ixazomib citrate and dexamethasone in treating patients with previously untreated symptomatic multiple myeloma or light chain amyloidosis. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as dexamethasone lower the body’s immune response and are used with other drugs in the treatment of some types of cancer. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide together with ixazomib citrate and dexamethasone may be a better treatment for multiple myeloma or light chain amyloidosis.
    Location: Mayo Clinic in Rochester, Rochester, Minnesota

  • Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)

    The purpose of this study is to determine the maximum tolerated dose (MTD) and / or recommended phase 2 dose (RP2D), safety and toxicity, and pharmacokinetics (PK) of ixazomib administered intravenously in combination with multiagent reinduction chemotherapy in pediatric participants with relapsed / refractory ALL or LLy.
    Location: 3 locations